$RXMD “The annualized pace we set in October equates to new records across the board as we continue to see broad-based top-line expansion on improving margins,” stated S. Parikh Mars, Progressive Care CEO. “Our $3.4 million in overall sales for October is an understatement because it leaves out the cash flows we took in during the month related to third-party billing activity. With all factors included, the number of gross billing would be closer to $4.2 million. And our 46k prescriptions filled puts Q4 on pace to handily surpass our breakout Q3 performance already. Execution continues to be tremendous, and I am very proud of our talented and dedicated team.”

The Company achieved over $3.4 million in overall October sales (not including an additional $800,000 third-party related billing activity), representing 78% annual growth in sales compared to October 2018, and 10% monthly growth in sales on a sequential monthly basis.


https://www.wsj.com/articles/PR-CO-20191119-905597